Enhanced potency of bivalent small molecule gp41 inhibitors

Bioorg Med Chem. 2017 Jan 1;25(1):408-420. doi: 10.1016/j.bmc.2016.11.010. Epub 2016 Nov 19.

Abstract

Low molecular weight peptidomimetic inhibitors with hydrophobic pocket binding properties and moderate fusion inhibitory activity against HIV-1 gp41-mediated cell fusion were elaborated by increasing the available surface area for interacting with the heptad repeat-1 (HR1) coiled coil on gp41. Two types of modifications were tested: 1) increasing the overall hydrophobicity of the molecules with an extension that could interact in the HR1 groove, and 2) forming symmetrical dimers with two peptidomimetic motifs that could potentially interact simultaneously in two hydrophobic pockets on the HR1 trimer. The latter approach was more successful, yielding 40-60times improved potency against HIV fusion over the monomers. Biophysical characterization, including equilibrium binding studies by fluorescence and kinetic analysis by Surface Plasmon Resonance, revealed that inhibitor potency was better correlated to off-rates than to binding affinity. Binding and kinetic data could be fit to a model of bidentate interaction of dimers with the HR1 trimer as an explanation for the slow off-rate, albeit with minimal cooperativity due to the highly flexible ligand structures. The strong cooperativity observed in fusion inhibitory activity of the dimers implied accentuated potency due to the transient nature of the targeted intermediate. Optimization of monomer, dimer or higher order structures has the potential to lead to highly potent non-peptide fusion inhibitors by targeting multiple hydrophobic pockets.

Keywords: Bivalent inhibitors; Cooperativity; Fluorescence; Fusion inhibition; HIV-1 gp41; Hydrophobic pocket; Kinetics; Peptidomimetic inhibitors; Surface plasmon resonance.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Binding Sites
  • Cell Fusion
  • HIV Envelope Protein gp41 / antagonists & inhibitors*
  • HIV Fusion Inhibitors / chemical synthesis
  • HIV Fusion Inhibitors / pharmacology*
  • HeLa Cells
  • Humans
  • Kinetics
  • Models, Chemical
  • Peptidomimetics / chemical synthesis
  • Peptidomimetics / pharmacology*

Substances

  • HIV Envelope Protein gp41
  • HIV Fusion Inhibitors
  • Peptidomimetics